MEI Pharma terminates Kyowa Kirin deal, regains full global rights to ME-401; urges vote for Infinity merger

Lite Strategy, Inc.

Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.
MEI regains full global rights to develop, manufacture and commercialize ME-401; Kyowa Kirin retains limited compassionate use until Nov 30, 2027.
Each party released the other from claims; MEI must deliver certain materials to Kyowa Kirin.
Press release reminds shareholders to vote FOR Infinity transaction at July 23 special meeting; ISS and Glass Lewis recommend FOR.

item 1.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lite Strategy, Inc. terminated Original Agreement with Kyowa Kirin Co., Ltd. (effective 2023-07-14).

Action: termination
Agreement: license
Counterparty: Kyowa Kirin Co., Ltd.
Effective: 2023-07-14

Exact text from the filing

On July 14, 2023, the Company and Kyowa Kirin entered into a Termination Agreement (the “Termination Agreement”) to mutually terminate the Original Agreement, effective July 14, 2023

View on SEC.gov

Browse all material agreements →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-189610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.